Orville Kolterman, MD, became the chief Medical Officer of Pendulum in 2014. Dr. Kolterman is an internationally respected diabetes expert that has been involved in advancing diabetes care for nearly 50 years. He successfully brought four GLP-1 drugs from research trials to market as the Chief Medical Officer at Amylin Pharmaceuticals. He’s held the role of Adjunct Processor of Medicine at the University of California, San Diego for over 20 years, and is a past President of the California Affiliate of the American Diabetes Association.
Dr. Kolterman completed his residency training in Endocrinology at Stanford University, his MD at the Stanford School of Medicine, and his BA at the University of Kansas.